Table S1.
Baseline characteristics of included studies on age-related macular degeneration
| Author | Year | Treatment | No of treatments | Age (years) | VA (ETDRS letters) | CMT (μm) | Follow-up (weeks) |
|---|---|---|---|---|---|---|---|
| Bashshur et al19 | 2007 | IVB 2.5 mg vs PDT | 2.4 vs 2.3 | 75 | 47 | 353 | 24 |
| Lazic and Gabric20 | 2007 | IVB 1.25 mg vs PDT vs IVB + PDT | NA | 75.7 | 46 | 353.4 | 12 |
| Parodi et al21 | 2010 | IVB 1.25 mg vs PDT vs laser | 3.8 vs 2.55 vs 1.17 | 49.98 | 71.89 | 234 | 104 |
| Sacu et al22 | 2009 | IVB 1 mg vs PDT + IVTA 4 mg | 6.8 vs 1.9 | 78 | 48 | 341 | 52 |
| Martin et al25 | 2011 | IVB 1.25 mg vs IVR 0.5 mg | 7.7 vs 6.9 | 78.85 | 60.95 | 459.5 | 52 |
| Gharbiya et al24 | 2010 | IVB 1.25 mg vs IVR 0.5 mg | 2.8 vs 2.4 | 59.84 | 27.97 | 244 | 24 |
| Biswas et al23 | 2011 | IVB 1.25 mg vs IVR 0.5 mg | 5.6 vs 4.3 | 63.9 | 57.52 | 286.4 | 72 |
| Subramanian et al26 | 2010 | IVB 1.25 mg vs IVR 0.5 mg | 8 vs 4 | 78.59 | 34.23 | 304.89 | 52 |
Abbreviations: VA, visual acuity; CMT, central macular thickness; ETDRS, early treatment diabetic retinopathy study; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; IVTA, intravitreal triamcinolone; NA, not applicable; PDT, photodynamic therapy.